Publications

Interplay of Age and Sex With Clinic and Ambulatory Blood Pressure and Mortality.

Böhm M. et al, (2026), Hypertension

ssociation Between 24-Hour Systolic Blood Pressure Time in Target Range and Mortality.

Lauder L. et al, (2026), Hypertension

SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria: A Meta-Analysis.

Neuen BL. et al, (2026), JAMA, 335, 233 - 244

Effects of Sodium Glucose Cotransporter 2 Inhibitors by Diabetes Status and Level of Albuminuria: A Meta-Analysis.

Staplin N. et al, (2026), JAMA, 335, 220 - 232

Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group ., (2026), Lancet Infect Dis, 26, 34 - 45

Effects of Empagliflozin on Kidney and Cardiac Magnetic Resonance Imaging Measures in Patients With CKD: An EMPA-KIDNEY Mechanistic Substudy.

Zhu D. et al, (2025), Am J Kidney Dis

Mortality according to ambulatory blood pressure in hypertensive patients with normal or impaired kidney function.

Gorostidi M. et al, (2025), Hypertens Res, 48, 3234 - 3243

n application of the MR-Horse method to reduce selection bias in genome-wide association studies of disease progression.

Donovan K. et al, (2025), Eur J Hum Genet, 33, 1677 - 1683

Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes: an individual participant-level meta-analysis.

Herrington WG. et al, (2025), Lancet Diabetes Endocrinol, 13, 1003 - 1014

Chronic kidney disease and incident cancer risk: an individual participant data meta-analysis.

Mok Y. et al, (2025), Br J Cancer, 133, 1535 - 1543

Blood Pressure and Mortality in Mexico City: A Mendelian Randomization Study.

Turner M. et al, (2025), Hypertension, 82, 1896 - 1905

Glucose Interference in Urine Biomarkers and Implications for Sodium-Glucose Cotransporter 2 Inhibition.

Malijan GB. et al, (2025), Kidney Int Rep, 10, 4090 - 4093

Effects of Empagliflozin on Urine Biomarkers in EMPA-KIDNEY.

Malijan GB. et al, (2025), Am J Kidney Dis

Glucose interference in urine biomarkers and implications for SGLT2 inhibition

Malijan G. et al, (2025), Kidney International Reports

Molnupiravir or nirmatrelvir-ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group ., (2025), Lancet Infect Dis, 25, 1000 - 1010

Search results (151)